PCRX Q3 2021 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$969M

Q3 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$128M+8.7% YoY

Gross Profit

$93M72.9% margin

Operating Income

$31M24.6% margin

Net Income

$18M13.8% margin

EPS (Diluted)

$0.39

QoQ Revenue Growth

-5.8%

Cash Flow

Operating Cash Flow

$60M

Free Cash Flow

$47M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$637M

Stockholders' Equity

$719M

Cash & Equivalents

$134M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$128M	$117M	+8.7%
Gross Profit	$93M	$87M	+6.4%
Operating Income	$31M	$18M	+78.4%
Net Income	$18M	$130M	-86.4%

Revenue Segments

Product

$127M99%

Royalty

$931,0001%